Daily Aspirin Treatment After Preeclampsia
Recruiting now · Early Phase 1 · Has a placebo group
Conditions studied: Preeclampsia
In brief
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Key facts
- Study ID
- NCT06168461
- Run by
- Anna Stanhewicz, PhD
- People needed
- 40
- Starts
- 2023-11-01
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2025-12-15
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- had preeclampsia in the past 5 years,
- 18 years or older
You may not qualify if…
- current daily aspirin use,
- skin diseases,
- current tobacco or nicotine use (including vaping),
- diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR < 60 mL/min/1.73m2,
- statin or other cholesterol-lowering medication,
- current antihypertensive medication,
- history of hypertension prior to pregnancy,
- history of gestational diabetes,
- currently pregnancy,
- body mass index <18.5 kg/m2,
- allergy to materials used during the experiment.(e.g. latex),
- known allergies to study drugs,
- bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Where it is running
- University of Iowa — Iowa City, Iowa, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.